Table 1. 50% Inhibitory Concentration (IC50) of Derivatives against AChE and 50% Effective Concentration EC50 on PC12 Cellsd.
| compound | IC50 (μM)a | EC50 (μM)b | compound | IC50 (μM)a | EC50 (μM)b |
|---|---|---|---|---|---|
| galantamine | 4.24 ± 1.65 | NDc | AMG-7 | 43.45 ± 5.27 | >100 |
| α-M | 34.28 ± 6.06 | >100 | AMG-8 | >100 | >100 |
| AMG | 41.21 ± 6.28 | >100 | AMG-9 | 45.97 ± 15.32 | >100 |
| edaravone | NDc | 69.98 ± 5.73 | AMG-10 | 47.78 ± 16.78 | 13.07 ± 2.25 |
| AMG-1 | 52.55 ± 11.27 | 1.61 ± 0.35 | AMG-11 | 43.60 ± 12.33 | 12.33 ± 4.65 |
| AMG-2 | 35.14 ± 9.38 | 12.77 ± 4.23 | AMG-12 | 19.20 ± 6.87 | >100 |
| AMG-3 | 32.89 ± 7.78 | 13.36 ± 5.17 | AMG-13 | 15.07 ± 3.56 | >100 |
| AMG-4 | >100 | 8.27 ± 2.01 | AMG-14 | 40.64 ± 13.78 | >100 |
| AMG-5 | >100 | >100 | AMG-15 | 34.46 ± 9.38 | >100 |
| AMG-6 | >100 | >100 | AMG-16 | 37.49 ± 11.24 | >100 |
a
Mean ± standard error of the mean (SEM) of three experiments for 50% inhibition of AChE.
b
Mean ± SEM of three independent experiments for 50% antioxidant neuroprotective effect.
c
Not determined.
d
Inhibitory activity (IC50, μM) of AChE and neuroprotective effective concentration (EC50, μM) for the studied compounds, galantamine and edaravone.